NASDAQ:BLRX

BioLineRx Stock Forecast, Price & News

$3.16

+0.07 (+2.27 %)

(As of 03/1/2021 12:00 AM ET)

Add

Compare

Today's Range

$3.11

Now: $3.16▼

$3.38

50-Day Range

$2.38

MA: $3.11▼

$4.00

52-Week Range

$1.06

Now: $3.16▼

$4.23

Volume930,568 shs

Average Volume2.81 million shs

Market Capitalization$123.41 million

P/E RatioN/A

Dividend YieldN/A

Beta2.08

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of solid tumors, hematological malignancies, and stem cell mobilization; AGI-134, an immuno-oncology agent in the development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of BL-8040 with KEYTRUDA (pembrolizumab) in pancreatic cancer; and Genentech Inc. to investigate the combination of BL-8040 and Genentech's TECENTRIQ (Atezolizumab) in Phase 1b/2 studies for solid tumors. BioLineRx Ltd. was founded in 2003 and is headquartered in Modi'in, Israel.

Headlines

Form POS AM BioLineRx Ltd. - StreetInsider.com
February 23, 2021 | streetinsider.com

BioLineRx Ltd. (BLRX) CEO Phil Serlin on Q4 2020 Results - Earnings Call Transcript - Seeking Alpha
February 23, 2021 | seekingalpha.com

BioLineRx Reports Year-End 2020 Financial Results and Provides Corporate Update - Yahoo Finance
February 23, 2021 | finance.yahoo.com

Form 6-K BioLineRx Ltd. For: Feb 23 - StreetInsider.com
February 23, 2021 | streetinsider.com

BioLineRx Reports Year-End 2020 Financial Results and Provides Corporate Update
February 23, 2021 | finance.yahoo.com

BioLineRx to Report Annual 2020 Results on February 23, 2021 - Yahoo Finance
February 17, 2021 | finance.yahoo.com

BioLineRx to Report Annual 2020 Results on February 23, 2021
February 17, 2021 | finance.yahoo.com

These 2 Penny Stocks Could Rally All the Way to $11, Say Analysts - Yahoo Finance
January 28, 2021 | finance.yahoo.com

BioLineRx: Investors Are About To Cash In On Motixafortide's Phase 3 Results - Seeking Alpha
January 27, 2021 | seekingalpha.com

BioLineRx Announces Closing of $34.5 Million Bought Deal Offering and Full Exercise of the Option of the Underwriter - PRNewswire
January 22, 2021 | prnewswire.com

BioLineRx Announces Closing of $34.5 Million Bought Deal Offering and Full Exercise of the Option of the Underwriter
January 22, 2021 | finance.yahoo.com

Obalon Therapeutics, Caladrius Biosciences leads healthcare gainers - Seeking Alpha
January 20, 2021 | seekingalpha.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:BLRX

Previous Symbol

CUSIPN/A

CIK1498403

Webwww.biolinerx.com

Phone972-8642-9100

Employees42

Year FoundedN/A

Debt

Debt-to-Equity Ratio0.14

Current Ratio2.05

Quick Ratio2.04

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$4.46 per share

Price / Book0.71

Profitability

EPS (Most Recent Fiscal Year)($2.55)

Net Income$-25,450,000.00

Net MarginsN/A

Return on Equity-96.27%

Return on Assets-55.87%

Miscellaneous

Outstanding Shares39,055,000

Market Cap$123.41 million

Next Earnings Date5/19/2021 (Estimated)

OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.57 out of 5 stars

Medical Sector

363rd out of 1,966 stocks

Pharmaceutical Preparations Industry

181st out of 772 stocks

3.5 Analyst's Opinion

Consensus Rating
BioLineRx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $15.00, BioLineRx has a forecasted upside of 374.7% from its current price of $3.16.
Amount of Analyst Coverage
BioLineRx has only been the subject of 1 research reports in the past 90 days.

3.1 Community Rank

Outperform Votes
BioLineRx has received 490 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
BioLineRx has received 300 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
BioLineRx has received 62.03% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about BioLineRx and other stocks. Vote “Outperform” if you believe BLRX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BLRX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
BioLineRx does not currently pay a dividend.
Dividend Growth
BioLineRx does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, BioLineRx insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.10% of the stock of BioLineRx is held by insiders.
Percentage Held by Institutions
Only 17.46% of the stock of BioLineRx is held by institutions.

1.3 Earnings and Valuation

Earnings Growth
Earnings for BioLineRx are expected to grow in the coming year, from ($1.42) to ($0.84) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of BioLineRx is -1.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of BioLineRx is -1.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
BioLineRx has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

$3.16

+0.07 (+2.27 %)

(As of 03/1/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive BLRX News and Ratings via Email

Sign-up to receive the latest news and ratings for BLRX and its competitors with MarketBeat's FREE daily newsletter.

BioLineRx (NASDAQ:BLRX) Frequently Asked Questions

Is BioLineRx a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioLineRx in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BioLineRx stock.
View analyst ratings for BioLineRx or view top-rated stocks.

What stocks does MarketBeat like better than BioLineRx?

Wall Street analysts have given BioLineRx a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but BioLineRx wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting BioLineRx?

BioLineRx saw a drop in short interest in the month of January. As of January 29th, there was short interest totaling 1,790,000 shares, a drop of 27.8% from the January 14th total of 2,480,000 shares. Based on an average daily volume of 2,550,000 shares, the short-interest ratio is currently 0.7 days.
View BioLineRx's Short Interest.

When is BioLineRx's next earnings date?

BioLineRx is scheduled to release its next quarterly earnings announcement on Wednesday, May 19th 2021.
View our earnings forecast for BioLineRx.

How were BioLineRx's earnings last quarter?

BioLineRx Ltd. (NASDAQ:BLRX) posted its quarterly earnings results on Monday, November, 23rd. The biotechnology company reported ($0.30) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.36) by $0.06.
View BioLineRx's earnings history.

How has BioLineRx's stock been impacted by COVID-19 (Coronavirus)?

BioLineRx's stock was trading at $1.60 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, BLRX shares have increased by 97.5% and is now trading at $3.16.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for BLRX?

2 Wall Street analysts have issued 12 month target prices for BioLineRx's stock. Their forecasts range from $11.00 to $19.00. On average, they anticipate BioLineRx's stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 374.7% from the stock's current price.
View analysts' price targets for BioLineRx or view top-rated stocks among Wall Street analysts.

Who are BioLineRx's key executives?

BioLineRx's management team includes the following people:

Mr. Philip A. Serlin CPA, M.B.A., CPA, MBA, Chief Exec. Officer (Age 61, Pay $469k)
Ms. Mali Zeevi CPA, CPA, Chief Financial Officer (Age 45, Pay $274k)
Dr. Ella Sorani, VP R&D (Age 53, Pay $301k)
Dr. Abi Vainstein-Haras, VP of Clinical Devel. (Age 46, Pay $299k)
Advocate Norman Kotler, Internal Enforcement Officer, Gen. Counsel and Corp. Sec. (Age 69)
Mr. Raziel Fried, Treasurer & Budgetary Control Director
Dr. Leah N Klapper, Consultant (Age 56)

Who are some of BioLineRx's key competitors?

Some companies that are related to BioLineRx include 89bio (ETNB), Wave Life Sciences (WVE), Akebia Therapeutics (AKBA), Avadel Pharmaceuticals (AVDL), Selecta Biosciences (SELB), Mirum Pharmaceuticals (MIRM), Aldeyra Therapeutics (ALDX), Inozyme Pharma (INZY), RAPT Therapeutics (RAPT), DURECT (DRRX), BioDelivery Sciences International (BDSI), TherapeuticsMD (TXMD), MEI Pharma (MEIP), Athersys (ATHX) and Orphazyme A/S (ORPH).
View all of BLRX's competitors.

What other stocks do shareholders of BioLineRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioLineRx investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), KushCo (KSHB), Aeterna Zentaris (AEZS), Cannabics Pharmaceuticals (CNBX), Pennsylvania Real Estate Investment Trust (PEI), Savara (SVRA), Bionano Genomics (BNGO) and Gran Tierra Energy (GTE).

What is BioLineRx's stock symbol?

BioLineRx trades on the NASDAQ under the ticker symbol "BLRX."

Who are BioLineRx's major shareholders?

BioLineRx's stock is owned by a number of institutional and retail investors. Top institutional shareholders include LPL Financial LLC (0.11%), Thomasville National Bank (0.09%) and Rhumbline Advisers (0.04%).

Which institutional investors are buying BioLineRx stock?

BLRX stock was purchased by a variety of institutional investors in the last quarter, including LPL Financial LLC, Rhumbline Advisers, and Thomasville National Bank.

How do I buy shares of BioLineRx?

Shares of BLRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioLineRx's stock price today?

One share of BLRX stock can currently be purchased for approximately $3.16.

How much money does BioLineRx make?

BioLineRx has a market capitalization of $123.41 million. The biotechnology company earns $-25,450,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis.

How many employees does BioLineRx have?

BioLineRx employs 42 workers across the globe.

What is BioLineRx's official website?

The official website for BioLineRx is www.biolinerx.com.

Where are BioLineRx's headquarters?

BioLineRx is headquartered at 2 HAMA-AYAN STREET, MODI-IN L3, 7177871.

How can I contact BioLineRx?

BioLineRx's mailing address is 2 HAMA-AYAN STREET, MODI-IN L3, 7177871. The biotechnology company can be reached via phone at 972-8642-9100 or via email at [email protected]

This page was last updated on 3/2/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here